COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,308 Articles (22,772 medRxiv, 8,536 bioRxiv)

Most recent first Previous |  Page 2047: Articles 20461-20470  | Next

Distribution of Incubation Period of COVID-19 in the Canadian Context: Modeling and Computational Study
Paul, S., Lorin, E.
10.1101/2020.11.20.20235648 — Posted: 2020-11-23
High resolution proximity statistics as early warning for US universities reopening during COVID-19
Mehrab, Z., Ranga, A. g., Sarkar, D., Venkatramanan, S., Chung Baek, Y., Swarup, S., Marathe, M.
10.1101/2020.11.21.20236042 — Posted: 2020-11-23
Biostatistical Investigation of Correlation Between COVID-19 and Diabetes Mellitus
Eynizadeh, Z., Ameli, Z., Sahranavard, M., Daneshparvar, M., Abdollahi Dolagh, M., Roozkhosh, M., Ejtehadi, M. R., Azimzadeh Irani, M.
10.1101/2020.11.21.20235853 — Posted: 2020-11-23
BCG vaccine derived peptides induce SARS-CoV-2 T cell cross-reactivity
Eggenhuizen, P. J., Ng, B. H., Chang, J., Fell, A. L., Wong, W. Y., Gan, P.-y., Holdsworth, S. R., Ooi, J. D.
10.1101/2020.11.21.20236018 — Posted: 2020-11-23 Discussion: Onsite
Predicting COVID19 Critical Care Beds - The London North-West University Healthcare Trust Experience
Naude, J., Taniparthi, M., Adams, K., Biggin-Lamming, J., Elias, R., Milner, P., Mohammed, I., Towers, M., Kuper, M.
10.1101/2020.11.20.20235226 — Posted: 2020-11-23
Persisting antibody response to SARS-CoV-2 in a local Austrian population
Ladage, D., Roesgen, D., Schreiner, C., Ladage, D., Adler, C., Harzer, O., Braun, R.
10.1101/2020.11.20.20232140 — Posted: 2020-11-23
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
Jagannathan, P., Andrews, J., Bonilla, H., Hedlin, H., Jacobson, K., Balasubramanian, V., Purington, N., Kamble, S., de Vries, C., Quintero, O., Feng, K., Ley, C., Winslow, D., Newberry, J., Edwards, K., Hislop, C., Choong, I., Maldonado, Y., Glenn, J., Bhatt, A., Blish, C., Wang, T., Khosla, C., Pinsky, B., Desai, M., Parsonnet, J., Singh, U.
10.1101/2020.11.18.20234161 — Posted: 2020-11-23
Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers
Berger, A., Ngo Nsoga, M.-T., Perez Rodriguez, F. J., Abi Aad, Y., Sattonnet, P., Gayet-Ageron, A., Jaksic, C., Torriani, G., Boehm, E., Kronig, I., Sacks, J. A., de Vos, M., Jacquerioz-Bausch, F., Chappuis, F., Kaiser, L., Schibler, M., Eckerle, I.
10.1101/2020.11.20.20235341 — Posted: 2020-11-23
The risk of COVID hospital admission and COVID mortality during the first COVID 19 wave with a special emphasis on Ethnic Minorities: an observational study of a single, deprived, multi ethnic UK health economy
Singh, B. M., Bateman, J., Viswanath, A., Klaire, V., Mahmud, S., Nevill, A. M., Dunmore, S. J.
10.1101/2020.11.20.20224691 — Posted: 2020-11-23
Quantifying the potential value of antigen-detection rapid diagnostic tests for COVID-19: a modelling analysis
Ricks, S., Kendall, E. A., Dowdy, D. W., Sacks, J. A., Schumacher, S. G., Arinaminpathy, N.
10.1101/2020.11.20.20235317 — Posted: 2020-11-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).